[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-378722-105":59,"doc-detail-378722-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","therapeutic-delivery-of-tumor-suppressor-mirnas-for-breast-cancer-treatment","Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment","","Breast cancer remains a major health threat, with improved screening and therapies lowering mortality while drug resistance and relapse continue to limit effective management. microRNAs (miRNAs) influence cancer progression by regulating networks tied to differentiation, proliferation, apoptosis, and metabolism, and dysregulated miRNAs contribute to tumor development. This review highlights tumor suppressor miRNAs in breast cancer and evaluates delivery systems enabling targeted miRNA transport to cancer cells. Approaches include carriers such as nanoparticles, PLGA, PEI, modified extracellular vesicles, dendrimers, and liposomes, alongside viral delivery and advanced hydrogel or complex strategies, while addressing challenges and future prospects.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-delivery-of-tumor-suppressor-mirnas-for-breast-cancer-treatment/378722/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-delivery-of-tumor-suppressor-mirnas-for-breast-cancer-treatment/378722.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is miRNA-based therapy considered for breast cancer treatment?","Question",{"text":113,"@type":114},"miRNAs regulate gene expression by interacting with messenger RNAs, affecting pathways involved in differentiation, proliferation, apoptosis, and metabolism. Tumor suppressor miRNAs are highlighted as having therapeutic capacity in breast cancer progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What are the main challenges in developing miRNA therapies for breast cancer?",{"text":118,"@type":114},"The review emphasizes delivery-system stability and efficacy as major obstacles, alongside persistent issues such as drug resistance and relapse that hinder systematic treatment.",{"name":120,"@type":111,"acceptedAnswer":121},"Which delivery carriers are discussed for delivering tumor suppressor miRNAs to cancer cells?",{"text":122,"@type":114},"The document covers delivery using carriers including nanoparticles, PLGA particles, PEI polymers, modified extracellular vesicles, dendrimers, and liposomes. It also mentions additional advanced strategies such as viral delivery, hydrogel triple-helix systems, and hyaluronic acid/protamine sulfate complexes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},378722,1790269374,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","biology   \nReview  \nTherapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment  \nSonali S. Shinde 1,†, Sakeel Ahmed 2,†, Jonaid Ahmad Malik 3,4, Umme Hani 5, Afreen Khanam 6, Faisal Ashraf Bhat 7, Suhail Ahmad Mir 8, Mohammed Ghazwani 5, Shadma Wahab 9, Nazima Haider 10 and Abdulrahman A. Almehizia 11, *  \nCitation: Shinde, S.S.; Ahmed, S.; Malik, J.A.; Hani, U.; Khanam, A.; Ashraf Bhat, F.; Ahmad Mir, S.; Ghazwani, M.; Wahab, S.; Haider, N.; et al. Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment. Biology 2023, 12, 467. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biology12030467  \nAcademic Editors: Paola Marcato and Suresh Gadde  \nReceived: 7 February 2023  \nRevised: 10 March 2023  \nAccepted: 16 March 2023  \nPublished: 19 March 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad 431004, India  \n2 Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Ahmedabad 382355, India  \n3 Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Guwahati 781101, India  \n4 Department of Biomedical Engineering, Indian Institute of Technology, Rupnagar 140001, India  \n5 Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia  \n6 Department of Pharmacognosy and Phytochemistry, Jamia Hamdard, New Delhi 110062, India  \n7 Department of Pharmacology, Jamia Hamdard, New Delhi 110062, India  \n8 Department of Pharmaceutical Sciences, University of Kashmir, Jammu and Kashmir, Hazratbal, Srinagar 190006, India  \n9 Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia  \n10 Department of Pathology, College of Medicine, King Khalid University, Abha 62529, Saudi Arabia  \n11 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia  \n* [Correspondence: mehizia@ksu.edu.sa](Correspondence: mehizia@ksu.edu.sa)[ ](Correspondence: mehizia@ksu.edu.sa)† These authors contributed equally to this work.  \nSimple Summary: The most frequent cancer in women is breast cancer (BC), which presents a significant risk to their good health. Over the past few decades, several factors have significantly affected BC progression and treatment. Additionally, microRNAs (miRNAs) that govern several oncogenesand tumor suppressors significantly control the expression networks during BC progression. Asa result, miRNA-based therapies that changes these networks may modify the cellular activity to the point where they can treat BC. However, the most substantial challenges in developing such miRNA therapies are the stability and efficacy of their delivery systems. A comprehensive update describing various tumor suppressor miRNAs (TS miRNAs) in BC and their various delivery systems are discussed in this review.  \nAbstract: The death rate from breast cancer (BC) has dropped due to early detection and sophisticated therapeutic options, yet drug resistance and relapse remain barriers to effective, systematic treatment. Multiple mechanisms underlying miRNAs appear crucial in practically every aspect of cancer progression, including carcinogenesis, metastasis, and drug resistance, as evidenced by the elucidation of drug resistance. Non-coding RNAs called microRNAs (miRNAs) attach to complementary messenger RNAs and degrade them to inhibit the expression and translation to proteins. Evidence suggests that miRNAs play a vital role in developing numerous diseases, including cancer. They","cbCaij4Q1vaAnlkn","https://ap.wps.com/l/cbCaij4Q1vaAnlkn","pdf",1688623,21,"English","# Introduction\n# Breast Cancer and miRNAs\n## Tumor Suppressor miRNAs and Their Therapeutic Potential\n## Barriers in miRNA Delivery\n# Therapeutic Delivery Approaches\n## Carrier-Based Delivery Systems","[{\"question\":\"Why is miRNA-based therapy considered for breast cancer treatment?\",\"answer\":\"miRNAs regulate gene expression by interacting with messenger RNAs, affecting pathways involved in differentiation, proliferation, apoptosis, and metabolism. Tumor suppressor miRNAs are highlighted as having therapeutic capacity in breast cancer progression.\"},{\"question\":\"What are the main challenges in developing miRNA therapies for breast cancer?\",\"answer\":\"The review emphasizes delivery-system stability and efficacy as major obstacles, alongside persistent issues such as drug resistance and relapse that hinder systematic treatment.\"},{\"question\":\"Which delivery carriers are discussed for delivering tumor suppressor miRNAs to cancer cells?\",\"answer\":\"The document covers delivery using carriers including nanoparticles, PLGA particles, PEI polymers, modified extracellular vesicles, dendrimers, and liposomes. It also mentions additional advanced strategies such as viral delivery, hydrogel triple-helix systems, and hyaluronic acid/protamine sulfate complexes.\"}]","Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment | PDF",1790232085,53]